SoBao Protein announced that the company will hold a semi-annual performance briefing on September 21, 2026. There was no increase in revenue and profit in the first half of the year, mainly because the increase in procurement costs of non-genetically modified soybeans was greater than the increase in product sales prices, exchange losses caused by the appreciation of the RMB exchange rate, and the increase in R&D investment by the subsidiary Yuanqi Special Medicine. The 30,000 ton soybean tissue brushed protein project is progressing steadily and is expected to be put into operation by December 2026; the 200,000 ton non-genetically-modified soybean industry chain processing project in Minde, Jilin was completed for trial production in June 2025; there are also projects under construction such as specialty food and production line transformation. As of September 20, 2026, the number of shareholders of the company was 14,726.

SoBao Protein announced that the company will hold a semi-annual performance briefing on September 21, 2026. There was no increase in revenue and profit in the first half of the year, mainly because the increase in procurement costs of non-genetically modified soybeans was greater than the increase in product sales prices, exchange losses caused by the appreciation of the RMB exchange rate, and the increase in R&D investment by the subsidiary Yuanqi Special Medicine. The 30,000 ton soybean tissue brushed protein project is progressing steadily and is expected to be put into operation by December 2026; the 200,000 ton non-genetically-modified soybean industry chain processing project in Minde, Jilin was completed for trial production in June 2025; there are also projects under construction such as specialty food and production line transformation. As of September 20, 2026, the number of shareholders of the company was 14,726.